leadf
logo-loader
viewCellmid Limited
(
ASX:CDY
)

Cellmid receives first shipment of COVID-19 rapid test kits

The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured in a facility certified by the Australian Therapeutic Goods Administration (TGA).

Cellmid Limited - Cellmid receives first shipment of COVID-19 rapid test kits
The current shipment is intended to be sold to medical practitioners

Cellmid Limited (ASX:CDY) has received its first shipment of 12,000 SARS-CoV-2 rapid diagnostic tests in Sydney.

The Wondfo Biotech manufactured SARS-CoV-2 point of care test (Wondfo POCT) detects antibodies to the SARS-CoV-2 (the virus causing COVID-19).

The presence of antibodies to SARS-CoV-2 confirms exposure and is likely to convey immunity to COVID-19.

Cellmid expects the Wondfo POCT to be largely used to facilitate return to work programs.

The current shipment is intended to be sold to medical practitioners subject to the completion of internal testing.

A limited number of tests will be held for external testing and research purposes.

Second order planned

Cellmid has received several hundred enquiries and expressions of interest to supply the Wondfo POCT to medical practitioners, hospitals and research groups.

The company is currently evaluating these requests and will be completing confirmatory testing in preparation for placing its second order with the manufacturer.

The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured in a facility certified by the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA) under the Medical Device Single Audit Program (MDSAP) and is authorised to export its devices to Australia.

Quick facts: Cellmid Limited

Follow
ASX:CDY

Price: 0.053 AUD

Market Cap: $9.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Cellmid expects to see strong revenue growth out of China ahead of...

Cellmid Ltd’s (ASX:CDY) Maria Halasz speaks to Proactive's Andrew Scott following the news it's received the first order from Ourui Health Management Limited (OHM) for the sale of its Japanese, Ju-Ju® and Lexilis® branded, anti-ageing hair and skincare products in China. The first order of...

on 27/1/21

2 min read